On June 30, 2020, Pushpam, Deepam; Bakhshi, Sameer published an article.Computed Properties of 380843-75-4 The title of the article was Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician’s perspective. And the article contained the following:
Meta-anal. of tyrosine kinase inhibitors pharmacol. in chronic myeloid leukemia patients. Upcoming concepts and related trials in the management of chronic myeloid leukemia (CML) along with future directions have been touched upon. Evidence acquisition: PubMed, Embase, Google, Cochrane library and Medline were searched to identify relevant literature for the review. Clinicaltrial.gov was searched for upcoming data and trials. Results: There are lot of gap in pharmacokinetics and pharmacodynamics of TKI. Imatinib appears to be the safest TKI. Newer TKI’s achieve better achievement of therapeutic milestones, deeper mol. response and less chances of progression of CML compared to imatinib. Newer TKI appears to be better choice for achieving TFR. When the objective is survival, imatinib is still the TKI of choice. Primary prophylaxis with antiplatelet drugs for TKI having cardiovascular and thromboembolic side effects should be considered. Conclusion: Pharmacogenetic data of TKI is still immature to guide in therapeutic decision making in clin. practice. There is need for further research in pharmacol. and pharmacogenomics of newer TKI’s. Randomized controlled trials are required to decide the optimum TKI for TFR. Safe and effective TKI for targeting T315I mutation, CML accelerated phase and blast crisis are an active area of research. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Computed Properties of 380843-75-4
The Article related to meta analysis chronic myeloid leukemia tyrosine kinase pharmacol, gene polymorphism and imatinib, pharmacology of tyrosine kinase inhibitors, selection of tyrosine kinase inhibitors, tyrosine kinase inhibitors in chronic myeloid leukemia and other aspects.Computed Properties of 380843-75-4
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics